Biocon continues to be the only Asian Company in the Prestigious Science Careers Top 20 Employers List, since 2012
Bengaluru, Karnataka, India, October 25, 2017
Biocon Ltd, Asia´s premier biopharmaceuticals company, has been ranked at No. 9 in The Science Careers Top 20 Employers Survey 2017. It is the only Asian company in the prestigious list of global biotech and pharma companies. Biocon has been recognized for ´being an innovative leader in the industry´, ´having a clear vision´ and ´being socially responsible´.
The Science and Science Careers’ 2017 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries to determine the best employers in these industries, as well as their driving characteristics. This year almost 7,000 people participated in the web-based survey, these respondents were from North America (65%), Europe (25%), and Asia/Pacific Rim (7%); 94% of these were from biotechnology, biopharmaceutical, and pharmaceutical companies.
The overall driving characteristics of top employers as per survey respondents are ´innovative leader in the industry´, ´work culture values aligned´, ´treats employees with respect´, ´is socially responsible´, ´has loyal employees´, and ´has clear visionv. The survey results are accessible here.
Mr Amitava Saha, Sr. Vice President & Head of HR, Biocon, said, “We are extremely proud to hold our position in Top 20 Best Employers, since 2012. This is a recognition of Biocon’s people centric work culture, which encourages innovative thinking, focuses on excellence, instils a sense of ownership and builds confidence in our employees to make a difference. These qualities have made us one of the most sought after employers among the top biotech & pharma companies in the world.”
Biocon is the only Company from Asia to feature in this list since 2012. Some of the other leading global players are Regeneron, Novozymes, NovoNordisk, Merck; Genentech, EliLilly etc.
Top 20 Employers for 2017:
2017 Science Careers Top Employers Survey Methodology:
The methodology included emailed invitations to roughly 26,000 individuals who were located worldwide. These individuals were AAAS members, Science website registrants, Science Careers registrants, and past survey respondents who opted in last year to take this year´s survey. The second part of the methodology included emailed invitations to approximately 400 human resource contacts at industry firms from the Science Careers database. A total of 6,950 surveys were submitted this year which is 15% more than last year´s total.
The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science (sciencemag.org) as well as Science Translational Medicine, Science Signaling, a digital, open-access journal, Science Advances, Science Immunology, and coming soon Science Robotics. AAAS was founded in 1848 and includes nearly 250 affiliated societies and academies of science, serving 10 million individuals. The non-profit AAAS (aaas.org) is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy, international programs, science education, public engagement, and more.
About Biocon Ltd:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India´s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 120 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from ‘Lab to Market’. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development. Visit: archive.biocon.com